Gene Biotherapeutics, Inc. is a biotechnology company in the clinical development stage, dedicated to researching and bringing to market angiogenic gene therapy treatments for cardiovascular conditions across the United States. Its primary investigational compound, Generx, an angiogenic gene therapy candidate, is currently undergoing Phase 3 clinical trials. Generx aims to offer a potential treatment for individuals suffering from myocardial ischemia and severe, intractable angina, typically caused by advanced coronary artery disease.